Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AK112 and Cadonilimab with Chemotherapy for First-line Metastatic Pancreatic Cancer
NCT06646055Phase 2Active, not recruiting
- Sponsor
- Akeso, Inc.
- Start
- Jan 2025
- Primary completion
- Dec 2026
- Modality
- Antibody Conjugates, Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of ivonescimab, cadonilimab in pancreatic ductal adenocarcinoma (PDAC), sponsored by Akeso, Inc.. Started Jan 2025; status: active, not recruiting.
02
Drugs
ivonescimabcadonilimab
03
Conditions
pancreatic ductal adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT06646055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06646055.